Vaccine Adjuvant Heightens Panel’s Worries About Rare Adverse Events With Heplisav
Executive Summary
FDA’s Vaccines and Related Biological Products Advisory Committee recommended 8 to 5 with one abstention that Dynavax acquire more safety data pre-licensure for its hepatitis B vaccine.